MEDIFAST (MED) Director Kiai Parsa Buys 43,150 Shares

What Happened
Kiai Parsa, a director of Medifast (MED), reported two open-market purchases on August 26, 2026, totaling 43,150 shares. The filing lists purchases of 41,975 shares at $12.26 (reported value $514,748) and 1,175 shares at $12.26 (reported value $14,409), for a combined reported cost of $529,157. These were purchases (net acquisitions), not sales.

Key Details

• Transaction date: 2026-08-26 (reported on Form 4 filed 2026-08-28 — filing appears timely).
• Reported prices: $12.26 average per share; filing footnote states actual trade prices ranged $12.12–$12.38.
• Shares purchased: 41,975 and 1,175 (total 43,150). Reported total value: $529,157.
• Shares owned after transaction: Not specified in the provided filing.
• Notable footnotes:
  • F1/F2/F3: Holdings are tied to Steamboat-managed funds (Steamboat Capital Partners Master Fund, LP and Steamboat Capital Partners II, LP); Parsa is managing member of the general partner and investment adviser and disclaims direct beneficial ownership except for any pecuniary interest.
  • F4: $12.26 shown is an average price; exact per-trade prices available on request.

Context
This filing shows an insider purchase reported by a director, executed via entities/funds tied to Steamboat Capital Partners. Purchases by insiders or affiliated investment vehicles are often watched by retail investors as a potential positive signal, but the filing includes a standard disclaimer that Parsa may only have a pecuniary interest through the funds rather than direct personal ownership. The report contains no option exercises, awards, gifts, tax-withholding events, or indications of a 10% owner change.